This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wahrenbrock, M. G. Articles by Varki, A. Search for Related Content PubMed PubMed Citation Articles by Wahrenbrock, M. G. Articles by Varki, A.

Multiple Hepatic Receptors Cooperate to Eliminate Secretory Mucins Aberrantly Entering the Bloodstream: Are Circulating Cancer Mucins the "Tip of the Iceberg"?

Glycobiology Research and Training Center, Departments of Medicine and Cellular and Molecular Medicine, University of California, San Diego, California

Requests for reprints: Ajit Varki, Glycobiology Research and Training Center, University of California, San Diego, 9500 Gilman Drive, CMM-East Room 1086, La Jolla, CA 92093-0687. Phone: 858-534-2214; Fax: 858-534-5611; E-mail: a1varki{at}ucsd.edu.

Hollow organs lined by columnar epithelial cells normally secrete mucins and their proteolytic fragments vectorially into the lumen. These heterogeneously O-glycosylated molecules are known to aberrantly enter the bloodstream in the setting of epithelial carcinomas and possibly during injury or inflammation. We have recently shown that carcinoma mucin fragments can trigger the rapid formation of platelet-rich microthrombi in vivo. Thus, mechanisms to clear such aberrantly secreted mucins must exist. Indeed, we found that i.v. injected carcinoma mucin fragments had an 1 minute half-life in mice, which was primarily due to rapid clearance by hepatic reticuloendothelial cells. Inhibition of known glycan-recognizing hepatic clearance receptors showed involvement of multiple partially overlapping clearance systems. Studies of genetically deficient mice and incomplete competition between different mucins confirmed this result. Thus, multiple hepatic clearance receptors cooperate to eliminate secretory mucins entering the circulation, limiting potential pathology. This may also explain why mucin-type clustered O-glycosylation is rare on plasma proteins. Notably, small subsets of injected carcinoma mucins remained unrecognized by clearance systems, had a much longer half-life, and carried highly sialylated O-glycans. Similar circulating mucins were found in tumor-bearing mice despite lack of saturation of hepatic clearance mechanisms. Thus, circulating cancer mucins currently used as clinical diagnostic markers likely represent only the clearance-resistant "tip of the iceberg." Such aberrantly circulating mucins could play pathologic roles not only in cancer but also during injury or inflammation of hollow organs and in liver disease. (Cancer Res 2006; 66(4): 2433-41)

This article has been cited by other articles:

				H. H. Wandall, K. M. Hoffmeister, A. L. Sorensen, V. Rumjantseva, H. Clausen, J. H. Hartwig, and S. J. Slichter Galactosylation does not prevent the rapid clearance of long-term, 4{degrees}C-stored platelets Blood, March 15, 2008; 111(6): 3249 - 3256. [Abstract] [Full Text] [PDF]

				A. Varki Trousseau's syndrome: multiple definitions and multiple mechanisms Blood, September 15, 2007; 110(6): 1723 - 1729. [Abstract] [Full Text] [PDF]